Published in Arch Gen Psychiatry on October 01, 2004
The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag (2009) 1.90
Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend (2008) 1.65
Illicit anabolic-androgenic steroid use. Horm Behav (2009) 1.35
Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev (2013) 1.33
Treatment of anabolic-androgenic steroid dependence: Emerging evidence and its implications. Drug Alcohol Depend (2010) 1.09
Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl (2012) 0.95
The dominance behavioral system and psychopathology: evidence from self-report, observational, and biological studies. Psychol Bull (2012) 0.93
Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology (2008) 0.92
Illicit use of androgens and other hormones: recent advances. Curr Opin Endocrinol Diabetes Obes (2012) 0.86
Pharmacologically induced hypogonadism and sexual function in healthy young women and men. Neuropsychopharmacology (2008) 0.83
Medical issues associated with anabolic steroid use: are they exaggerated? J Sports Sci Med (2006) 0.82
Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem. Addiction (2015) 0.82
Partial androgen deficiency, depression, and testosterone supplementation in aging men. Int J Endocrinol (2012) 0.80
Hormone treatment of depression. Dialogues Clin Neurosci (2011) 0.77
Androgens and male aging: Current evidence of safety and efficacy. Asian J Androl (2010) 0.77
National Athletic Trainers' Association position statement: anabolic-androgenic steroids. J Athl Train (2012) 0.77
Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study. PLoS One (2016) 0.75
Mirtazapine Is Effective in Steroid Withdrawal Syndrome Related Depression: A Case Report. Clin Psychopharmacol Neurosci (2017) 0.75
Alcoholism and sexual dimorphism in the middle longitudinal fascicle: a pilot study. Brain Imaging Behav (2016) 0.75
Effects of Sex Steroids in the Human Brain. Mol Neurobiol (2016) 0.75
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
Out of sight, out of mind: mental illness behind bars. Am J Psychiatry (2014) 1.98
Endocrine factors in the etiology of postpartum depression. Compr Psychiatry (2003) 1.55
A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry (2004) 1.47
Treatment strategies after SSRI failure--good news and bad news. N Engl J Med (2006) 1.46
Cognitive performance in healthy women during induced hypogonadism and ovarian steroid addback. Arch Womens Ment Health (2012) 1.45
Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition. Menopause (2016) 1.41
National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry (2002) 1.29
Sex hormones and mood in the perimenopause. Ann N Y Acad Sci (2009) 1.20
Sex-related differences in neuronal cell survival and signaling in rats. Neurosci Lett (2003) 1.17
Feasibility and diagnostic validity of the M-3 checklist: a brief, self-rated screen for depressive, bipolar, anxiety, and post-traumatic stress disorders in primary care. Ann Fam Med (2010) 1.16
Effects of ovarian hormones on human cortical excitability. Ann Neurol (2002) 1.14
Cortisol response to ovine corticotropin-releasing hormone in a model of pregnancy and parturition in euthymic women with and without a history of postpartum depression. J Clin Endocrinol Metab (2004) 1.12
Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry (2007) 1.12
Differential menstrual cycle regulation of hypothalamic-pituitary-adrenal axis in women with premenstrual syndrome and controls. J Clin Endocrinol Metab (2003) 1.11
Abnormal luteal phase excitability of the motor cortex in women with premenstrual syndrome. Biol Psychiatry (2003) 1.09
Testosterone suppression of CRH-stimulated cortisol in men. Neuropsychopharmacology (2005) 1.08
Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry (2005) 1.07
Alteration in estrogen receptor alpha mRNA levels in frontal cortex and hippocampus of patients with major mental illness. Biol Psychiatry (2005) 1.05
Shyness, social anxiety, and impaired self-esteem in Turner syndrome and premature ovarian failure. JAMA (2006) 1.04
Psychiatric symptoms and proinflammatory cytokines in pregnancy. Psychosom Med (2011) 0.99
A cross-sectional evaluation of perimenopausal depression. J Clin Psychiatry (2008) 0.95
A history of depression in women is associated with an altered GABAergic neuroactive steroid profile. Psychoneuroendocrinology (2011) 0.95
Sex-related differences in stimulated hypothalamic-pituitary-adrenal axis during induced gonadal suppression. J Clin Endocrinol Metab (2005) 0.93
Allopregnanolone as a mediator of affective switching in reproductive mood disorders. Psychopharmacology (Berl) (2014) 0.92
Concordant restoration of ovarian function and mood in perimenopausal depression. Am J Psychiatry (2003) 0.92
Operationalizing DSM-IV criteria for PMDD: selecting symptomatic and asymptomatic cycles for research. J Psychiatr Res (2002) 0.91
Antidepressant treatment during pregnancy: between Scylla and Charybdis. Am J Psychiatry (2006) 0.90
Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Am J Psychiatry (2002) 0.89
Abnormalities of dorsolateral prefrontal function in women with premenstrual dysphoric disorder: a multimodal neuroimaging study. Am J Psychiatry (2013) 0.89
Reproductive outcomes and risk of subsequent illness in women diagnosed with postpartum psychosis. Bipolar Disord (2013) 0.88
Antecedent trauma exposure and risk of depression in the perinatal period. J Clin Psychiatry (2013) 0.88
Dehydroepiandrosterone (DHEA) and its sulfated derivative (DHEAS) regulate apoptosis during neurogenesis by triggering the Akt signaling pathway in opposing ways. Brain Res Mol Brain Res (2002) 0.87
Current and lifetime psychiatric illness in women with Turner syndrome. Gynecol Endocrinol (2004) 0.87
Sex-related differences in MAPKs activation in rat astrocytes: effects of estrogen on cell death. Brain Res Mol Brain Res (2002) 0.87
Reproductive aging, sex steroids, and mood disorders. Harv Rev Psychiatry (2009) 0.86
Estradiol modulates anhedonia and behavioral despair in rats and negative affect in a subgroup of women at high risk for postpartum depression. Physiol Behav (2013) 0.84
Rapid response to fluoxetine in women with premenstrual dysphoric disorder. Depress Anxiety (2012) 0.84
Differentiation of women with premenstrual dysphoric disorder, recurrent brief depression, and healthy controls by daily mood rating dynamics. J Psychiatr Res (2007) 0.83
Magnesium (mg) retention and mood effects after intravenous mg infusion in premenstrual dysphoric disorder. Biol Psychiatry (2005) 0.83
Pharmacologically induced hypogonadism and sexual function in healthy young women and men. Neuropsychopharmacology (2008) 0.83
Estrogen effects on the forced swim test differ in two outbred rat strains. Physiol Behav (2012) 0.81
Premenstrual symptoms and perimenopausal depression. Am J Psychiatry (2006) 0.81
The menopause transition: the next neuroendocrine frontier. Expert Rev Neurother (2007) 0.80
Reproductive ageing, sex steroids and depression. J Br Menopause Soc (2006) 0.80
Depression in women with spontaneous 46, XX primary ovarian insufficiency. J Clin Endocrinol Metab (2010) 0.79
Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics. J Psychiatr Res (2010) 0.79
The association of migraine with menstrually related mood disorders and childhood sexual abuse. J Womens Health (Larchmt) (2013) 0.79
Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. Menopause (2014) 0.78
Effects of pharmacologically induced hypogonadism on mood and behavior in healthy young women. Am J Psychiatry (2013) 0.78
ACTH and cortisol response to Dex/CRH testing in women with and without premenstrual dysphoria during GnRH agonist-induced hypogonadism and ovarian steroid replacement. J Clin Endocrinol Metab (2012) 0.78
Monoamines and neurosteroids in sexual function during induced hypogonadism in healthy men. Arch Gen Psychiatry (2006) 0.77
The need for comprehensive psychiatric perinatal care-the University of North Carolina at Chapel Hill, Department of Psychiatry, Center for Women's Mood Disorders launches the first dedicated Inpatient Program in the United States. Am J Obstet Gynecol (2009) 0.77
DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEA's antidepressant action. Psychopharmacology (Berl) (2015) 0.76
History of postpartum depression in a clinic-based sample of women with premenstrual dysphoric disorder. J Clin Psychiatry (2016) 0.76
Reproductive hormonal treatments for mood disorders in women. Dialogues Clin Neurosci (2002) 0.76
Estrogen receptor alpha (ESR-1) associations with psychological traits in women with PMDD and controls. J Psychiatr Res (2010) 0.76
Low CSF somatostatin associated with response to nimodipine in patents with affective illness. Biol Psychiatry (2003) 0.76
Cardiovascular, hemodynamic, neuroendocrine, and inflammatory markers in women with and without vasomotor symptoms. Menopause (2016) 0.75
It is time to take a stand for medical research and against terrorism targeting medical scientists. Biol Psychiatry (2008) 0.75
Why study reproductive neuroscience? A clinical perspective. J Clin Psychiatry (2008) 0.75
Perimenopausal depression and early menopause: cause or consequence? Menopause (2017) 0.75
UNC Health Systems and Blue Cross and Blue Shield of North Carolina patient-centered medical home collaborative. N C Med J (2011) 0.75
Corrigendum: Hormonal gain control of a medial preoptic area social reward circuit. Nat Neurosci (2017) 0.75
Erratum to: DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEA's antidepressant action. Psychopharmacology (Berl) (2015) 0.75